Tommaso Mari

Tommaso Mari

Auto-generated profile, based on publicly available information

Tommaso Mari

Bayer, AG, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2021 in Cell
Verified
Journal Article
Closed access
DWDaniel Wendisch
Daniel Wendisch
ODOliver Dietrich
Oliver Dietrich
TMTommaso Mari
Tommaso Mari
SSSaskia von Stillfried
Saskia von Stillfried
IIIgnacio L. Ibarra
Ignacio L. Ibarra
LSLeif Erik Sander
Leif Erik Sander

1 March 2021 in iScience
Verified
Journal Article
Open access
EWEmanuel Wyler
Emanuel Wyler
KMKirstin Mösbauer
Kirstin Mösbauer
VFVedran Franke
Vedran Franke
ADAsija Diag
Asija Diag
LGLina Theresa Gottula
Lina Theresa Gottula
MLMarkus Landthaler
Markus Landthaler
Detailed knowledge of the molecular biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is crucial for understanding of viral replication, host responses, and disease progression. Here, we report gene expression profiles of three SARS-CoV- and SARS-CoV-2-infected human cell lines. SARS-CoV-2 elicited an approximately two-fold higher stimulation of the innate immune response compared to SARS-CoV in the human epithelial cell line Calu-3, including induction of miRNA-155. Single-cell RNA sequencing of infected cells showed that genes induced by virus infections were broadly upregulated, whereas interferon beta/lambda genes, a pro-inflammatory cytokines such as IL-6, were expressed only in small subsets of infected cells. Temporal analysis suggested that transcriptional activities of interferon regulatory factors precede those of nuclear factor κB. Lastly, we identified heat shock protein 90 (HSP90) as a protein relevant for the infection. Inhibition of the HSP90 activity resulted in a reduction of viral replication and pro-inflammatory cytokine expression in primary human airway epithelial cells.

24 May 2022 in Journal of Proteome Research
Verified
Journal Article
Closed access
TMTommaso Mari
Tommaso Mari
KMKirstin Mösbauer
Kirstin Mösbauer
EWEmanuel Wyler
Emanuel Wyler
MLMarkus Landthaler
Markus Landthaler
CDChristian Drosten
Christian Drosten
MSMatthias Selbach
Matthias Selbach

13 September 2017 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MSMonica Soldi
Monica Soldi
TMTommaso Mari
Tommaso Mari
LNLuciano Nicosia
Luciano Nicosia
DMDaniele Musiani
Daniele Musiani
GSGianluca Sigismondo
Gianluca Sigismondo
Tiziana BonaldiTiziana Bonaldi
Tiziana Bonaldi
The integrated activity of cis-regulatory elements fine-tunes transcriptional programs of mammalian cells by recruiting cell type–specific as well as ubiquitous transcription factors (TFs). Despite their key role in modulating transcription, enhancers are still poorly characterized at the molecular level, and their limited DNA sequence conservation in evolution and variable distance from target genes make their unbiased identification challenging. The coexistence of high mono-methylation and low tri-methylation levels of lysine 4 of histone H3 is considered a signature of enhancers, but a comprehensive view of histone modifications associated to enhancers is still lacking. By combining chromatin immunoprecipitation (ChIP) with mass spectrometry, we investigated cis-regulatory regions in macrophages to comprehensively identify histone marks specifically associated with enhancers, and to profile their dynamics after transcriptional activation elicited by an inflammatory stimulation. The intersection of the proteomics data with ChIP-seq and RNA-seq analyses revealed the existence of novel subpopulations of enhancers, marked by specific histone modification signatures: specifically, H3K4me1/K36me2 marks transcribed enhancers, while H3K4me1/K36me3 and H3K4me1/K79me2 combinations mark distinct classes of intronic enhancers. Thus, our MS analysis of functionally distinct genomic regions revealed the combinatorial code of histone modifications, highlighting the potential of proteomics in addressing fundamental questions in epigenetics.

20 January 2021 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
FIFrancesca Imbastari
Francesca Imbastari
MDMathias Dahlmann
Mathias Dahlmann
ASAnje Sporbert
Anje Sporbert
CMCamilla Ciolli Mattioli
Camilla Ciolli Mattioli
TMTommaso Mari
Tommaso Mari
Ulrike SteinUlrike Stein
Ulrike Stein
Metastasis Associated in Colon Cancer 1 (MACC1) is a novel prognostic, predictive and causal biomarker for tumor progression and metastasis in many cancer types, including colorectal cancer. Besides its clinical value, little is known about its molecular function. Its similarity to SH3BP4, involved in regulating uptake and recycling of transmembrane receptors, suggests a role of MACC1 in endocytosis. By exploring the MACC1 interactome, we identified the clathrin-mediated endocytosis (CME)-associated proteins CLTC, DNM2 and AP-2 as MACC1 binding partners. We unveiled a MACC1-dependent routing of internalized transferrin receptor towards recycling. Elevated MACC1 expression caused also the activation and internalization of EGFR, a higher rate of receptor recycling, as well as earlier and stronger receptor activation and downstream signaling. These effects are limited by deletion of CME-related protein interaction sites in MACC1. Thus, MACC1 regulates CME and receptor recycling, causing increased growth factor-mediated downstream signaling and cell proliferation. This novel mechanism unveils potential therapeutic intervention points restricting MACC1-driven metastasis.

4 November 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
MDMathurin Dorel
Mathurin Dorel
BKBertram Klinger
Bertram Klinger
TMTommaso Mari
Tommaso Mari
JTJoern Toedling
Joern Toedling
EBEric Blanc
Eric Blanc
NBNils Blüthgen
Nils Blüthgen
Very high risk neuroblastoma is characterised by increased MAPK signalling, and targeting MAPK signalling is a promising therapeutic strategy. We used a deeply characterised panel of neuroblastoma cell lines and found that the sensitivity to MEK inhibitors varied drastically between these cell lines. By generating quantitative perturbation data and mathematical modelling, we determined potential resistance mechanisms. We found that negative feedbacks within MAPK signalling and via the IGF receptor mediate re-activation of MAPK signalling upon treatment in resistant cell lines. By using cell-line specific models, we predict that combinations of MEK inhibitors with RAF or IGFR inhibitors can overcome resistance, and tested these predictions experimentally. In addition, phospho-proteomic profiling confirmed the cell-specific feedback effects and synergy of MEK and IGFR targeted treatment. Our study shows that a quantitative understanding of signalling and feedback mechanisms facilitated by models can help to develop and optimise therapeutic strategies. Our findings should be considered for the planning of future clinical trials introducing MEKi in the treatment of neuroblastoma.